Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q3 EPS of ($0.61), $0.33 better than the analyst estimate of ($0.94). Revenue for the quarter came in at $48.1 million versus the consensus estimate of $43.18 million.

For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.